In hyperphosphatemic 5/6-nephrectomized rats, doxercalciferol lowered serum PTH while increasing serum calcium and the calcium–phosphate product. These mineral changes limit interpretation of PTH suppression as a uniformly favorable response. The PTH-mRNA figure does not mark a significant doxercalciferol-versus-vehicle reduction. [3]
PTH suppression and mineral changes in hyperphosphatemic uremic rats
Animal study · Male Sprague-Dawley rats after 5/6 nephrectomy, fed a hyperphosphatemia-inducing diet; n = 8–11 per group. [3]
In this two-week treatment cohort, doxercalciferol reduced serum PTH relative to NX vehicle while increasing total and ionized calcium and the calcium–phosphate product. The PTH-mRNA bar was lower than NX vehicle, but Figure 4 does not mark this doxercalciferol comparison as significant versus NX vehicle.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Three times per week
- Treatment course
- Two weeks after four weeks on the hyperphosphatemia-inducing diet
- Vehicle
- 5% ethanol + 95% propylene glycol, 0.4 mL/kg
- Doxercalciferol, hyperphosphatemic NX rats
- Model: Male Sprague-Dawley 5/6 NX rats on 0.9% phosphorus/0.6% calcium diet
- Reported limits: No Adooq lot testing is established.
Methods and source locations
Compound reported in the paper: Doxercalciferol; Compound label in the paper: 1α-hydroxyvitamin D2
Animal pharmacology of parent doxercalciferol; the separate active-metabolite pig-cell results are not parent-compound evidence.
Methods 2.1–2.4; Results hyperphosphatemic-diet cohort; Table 1; Figure 4 and caption
Serum intact PTH: Rat intact PTH ELISA — Table 1 (values and significance); Figure 4(a) (pg/mL unit); Methods 2.3
Total serum calcium: Abbott Aeroset — Table 1; Methods 2.3
Serum calcium × phosphate product: Product of measured total serum calcium and phosphate — Table 1
Total serum phosphate: Abbott Aeroset — Table 1; Results hyperphosphatemic-diet cohort; Methods 2.3
Parathyroid PTH mRNA: Real-time RT-PCR, normalized to GAPDH and expressed relative to sham vehicle (100%) — Figure 4(b) and caption; Methods 2.4
Doxercalciferol, hyperphosphatemic NX rats · Methods 2.1–2.4; Results hyperphosphatemic-diet cohort; Table 1; Figure 4 and caption
Low-dose doxercalciferol response depends on podocyte VDR expression in diabetic mice
Animal study · STZ-diabetic male DBA/2J wild-type and podocyte human-VDR transgenic mice; n = 7–9 per group. [1]
At 30 ng/kg for 16 weeks, doxercalciferol had little effect on albuminuria in wild-type mice, whereas the transgenic treatment group showed much lower albuminuria. Vehicle-treated transgenic mice also had less albuminuria than wild-type vehicle controls. This supports a VDR-associated, genotype-dependent response, not a receptor-binding potency estimate.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Three times per week
- Treatment course
- 16 weeks
- Vehicle
- 60:40 propylene glycol/H2O
- Wild-type + doxercalciferol
- Model: Diabetic male DBA/2J WT mice
- Reported limits: No Adooq lot testing is established.
- Podocyte hVDR transgenic + doxercalciferol
- Model: Diabetic male DBA/2J mice with podocyte-targeted human VDR transgene
- Reported limits: No Adooq lot testing is established.
Methods and source locations
Compound reported in the paper: Doxercalciferol; Compound label in the paper: Dox
Low-dose parent-compound animal response in a genetically modified diabetic mouse model; no Adooq lot validation or universal renoprotection claim.
Results paragraph beginning “We subjected WT and Tg mice”; Figure 2(a) and caption; Table 1; Concise Methods: Diabetic Animal Models and Treatment
Urinary albumin-to-creatinine ratio over time: Urinary albumin and creatinine measured with commercial kits; spot urine collected monthly — Figure 2(a) and caption; Results second experiment paragraph; Concise Methods: Diabetic Animal Models and Treatment
Wild-type + doxercalciferol · Results paragraph beginning “We subjected WT and Tg mice”; Figure 2(a) and caption; Table 1; Concise Methods: Diabetic Animal Models and Treatment
Podocyte hVDR transgenic + doxercalciferol · Results paragraph beginning “We subjected WT and Tg mice”; Figure 2(a) and caption; Table 1; Concise Methods: Diabetic Animal Models and Treatment